Hematocrit / CBC
The TRT Polycythemia Monitor and the >54% Threshold
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- A routine hematology measurement (complete blood count) run on automated analyzers.
Reference only. Not medical advice.
What can go wrong
Testosterone-induced erythrocytosis raises blood viscosity and is the most common laboratory abnormality on TRT. Although randomized-trial event rates for thrombosis have been low, the guideline threshold (>54%) reflects genuine concern in higher-risk men (smokers, sleep apnea, high baseline hematocrit). Supraphysiological or self-directed dosing without CBC monitoring is the dangerous scenario.
This is something to take to a clinician. The Atlas can tell you what is known about hematocrit / cbc in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The complete blood count, and specifically hematocrit (the percentage of blood volume that is red cells), is the primary safety monitor for testosterone-induced erythrocytosis (secondary polycythemia). Testosterone stimulates erythropoiesis, and a subset of men - especially on injectable esters - develop rising hematocrit, which raises blood viscosity and theoretical thrombotic risk. The Endocrine Society (2018) recommends withholding testosterone when hematocrit exceeds 54% until it normalizes, then resuming at a lower dose; the AUA flags 50% as a point to investigate and 54% to hold. This is guideline-mandated monitoring that many DTC and gym-sourced protocols ignore.
The cheapest, most important safety test on TRT - and the most skipped.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone increases erythropoiesis via erythropoietin stimulation and suppression of hepcidin, raising red-cell mass and hematocrit. Injectable esters, with their supraphysiological peaks, drive the largest rises; gels and other steady-state formulations do less. Rising hematocrit increases whole-blood viscosity; while the absolute event rate in trials has been low, the guideline threshold exists as a conservative safety brake.
The catch: the monitor is only useful if someone reads it
Erythrocytosis is common, silent, and detectable with a cheap test - which makes skipping the CBC one of the clearest failures of unmonitored testosterone use. Men self-sourcing testosterone, or on high-friction telehealth plans that do not enforce follow-up bloodwork, can climb well past 54% without knowing. Management (dose reduction, switching off injectables, or therapeutic phlebotomy) is straightforward once detected; the harm comes from not looking.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration of testosterone without CBC and other monitoring carries documented health risks, including erythrocytosis.
Replacement is not the same as a cycle
At physiological replacement doses, erythrocytosis is a manageable, monitorable effect; at supraphysiological/anabolic doses - and with injectable esters producing high peaks - hematocrit rises are larger and more frequent, amplifying viscosity-related risk. The CBC is the monitor that distinguishes a safe replacement course from a dangerous one.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Baseline hematocrit/CBC
- Repeat at 3-6 months then annually
- Withhold/reduce testosterone if hematocrit >54%
What people get wrong
Often saidHigh hematocrit on TRT just means you're well hydrated or fit
ActuallyOn testosterone, a rising hematocrit is most likely drug-induced erythrocytosis and is the guideline trigger to reduce dose or hold therapy.
Often saidIf you feel fine, you don't need CBC monitoring
ActuallyErythrocytosis is silent. The CBC is how it is caught before it climbs; skipping it removes the main TRT safety net.
Often saidPhlebotomy fully solves the problem so dose doesn't matter
ActuallyPhlebotomy manages hematocrit but does not address the supraphysiological dosing often driving it; formulation and dose changes are part of guideline management.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- What hematocrit measures
- % of blood volume that is red cells
- Mechanism on TRT
- Testosterone stimulates erythropoiesis / erythrocytosis
- Endocrine Society action threshold
- >54%: withhold T, resume lower dose after normalizing
- AUA thresholds
- 50% investigate; >=54% reduce/hold
- Highest-risk formulation
- Injectable testosterone esters (peaks/troughs)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hematocrit / CBC. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Bhasin et al., Endocrine Society guideline2018
Recommends measuring hematocrit at baseline, 3-6 months, and annually; withhold testosterone if hematocrit exceeds 54%
TRAVERSE cardiovascular safety trial (Lincoff et al., NEJM)2023
Large RCT of ~5,246 men; testosterone did not increase major cardiovascular events overall but showed more pulmonary embolism and other signals, keeping erythrocytosis monitoring relevant
Systematic reviews of testosterone and erythrocytosis2010s-2020s
Confirmed injectable esters carry the highest erythrocytosis risk versus transdermal formulations